KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Net Income towards Common Stockholders (2016 - 2026)

Bristol Myers Squibb has reported Net Income towards Common Stockholders over the past 18 years, most recently at $2.7 billion for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 8.81% to $2.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.3 billion through Mar 2026, up 36.58% year-over-year, with the annual reading at $7.1 billion for FY2025, 178.99% up from the prior year.
  • Net Income towards Common Stockholders was $2.7 billion for Q1 2026 at Bristol Myers Squibb, up from $1.1 billion in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
  • The 5-year median for Net Income towards Common Stockholders is $1.6 billion (2024), against an average of $883.5 million.
  • Year-over-year, Net Income towards Common Stockholders plummeted 625.28% in 2024 and then soared 1328.95% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then tumbled by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Net Income towards Common Stockholders are $2.7 billion (Q1 2026), $1.1 billion (Q4 2025), and $2.2 billion (Q3 2025).